Detalhe da pesquisa
1.
A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Clin Pharmacol Drug Dev
; 12(6): 611-624, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37125450
2.
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials.
RMD Open
; 7(2)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011674
3.
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Arthritis Rheumatol
; 73(3): 472-477, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33010188
4.
Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo.
Mol Cancer Ther
; 5(1): 160-9, 2006 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-16432175
5.
Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells.
J Med Chem
; 48(4): 909-12, 2005 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-15715460
6.
Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
J Rheumatol
; 42(10): 1752-60, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26233509
7.
JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Mol Cancer Ther
; 8(11): 3151-61, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19887542
8.
Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design.
Bioorg Med Chem Lett
; 16(12): 3310-4, 2006 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16600594